← Leaderboards
Bogdan Olenyuk
California Institute Of Technology
$9,097,017
Attributed
$11,026,394
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,026,394 · 7
By mechanism
R01$8,774,194 · 4
P01$1,883,611 · 1
R21$336,173 · 1
F32$32,416 · 1
Top collaborators
- Peter J Stang5 shared
- James S Hagood2 shared
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsDesignSolid NeoplasmPropertyCancer TherapyBindingTumorEndothelial CellsBaseNeoplasm MetastasisPathway InteractionsIn VivoEndotheliumAffinityTargeted DeliveryCaveolaeSolidTargeted TreatmentDrug Delivery SystemsPumpAntibodiesDosePharmaceutical PreparationsToxic Effect
Grant awards (24)
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$782,151
R01 · FY2025 · HL · contact PI
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$805,845
R01 · FY2024 · HL · contact PI
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$680,774
R01 · FY2023 · CA · contact PI
Development of caveolae-targeted antibody-drug conjugates$237,711
P01 · FY2023 · CA · contact PI
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$694,745
R01 · FY2022 · CA · contact PI
Development of caveolae-targeted antibody-drug conjugates$254,425
P01 · FY2022 · CA · contact PI
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$722,712
R01 · FY2021 · CA · contact PI
Development of caveolae-targeted antibody-drug conjugates$439,725
P01 · FY2021 · CA · contact PI
Active Delivery of Platinum Nanoimmunoconjugates to Improve Breast Cancer Therapy$432,336
R01 · FY2021 · CA · contact PI
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$735,974
R01 · FY2020 · CA · contact PI
Active Delivery of Platinum Nanoimmunoconjugates to Improve Breast Cancer Therapy$464,041
R01 · FY2020 · CA · contact PI
Development of caveolae-targeted antibody-drug conjugates$441,222
P01 · FY2020 · CA · contact PI
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$749,235
R01 · FY2019 · CA · contact PI
Development of caveolae-targeted antibody-drug conjugates$510,528
P01 · FY2019 · CA · contact PI
Active Delivery of Platinum Nanoimmunoconjugates to Improve Breast Cancer Therapy$444,921
R01 · FY2019 · CA · contact PI
Active Delivery of Platinum Nanoimmunoconjugates to Improve Breast Cancer Therapy$459,080
R01 · FY2018 · CA · contact PI
Small Molecule Protein Ligands as Modulators of Hypoxia-Inducible Transcription$333,000
R01 · FY2018 · GM · contact PI
Active Delivery of Platinum Nanoimmunoconjugates to Improve Breast Cancer Therapy$470,380
R01 · FY2017 · CA · contact PI
Small Molecule Protein Ligands as Modulators of Hypoxia-Inducible Transcription$333,000
R01 · FY2017 · GM · contact PI
Small Molecule Protein Ligands as Modulators of Hypoxia-Inducible Transcription$333,000
R01 · FY2016 · GM · contact PI
Small Molecule Protein Ligands as Modulators of Hypoxia-Inducible Transcription$333,000
R01 · FY2015 · GM · contact PI
Modular Dendritic Integrin Antagonists for Cancer Therapy$117,752
R21 · FY2008 · CA · contact PI
Modular Dendritic Integrin Antagonists for Cancer Therapy$218,421
R21 · FY2007 · CA · contact PI
DESIGN OF SEQUENCE SPECIFIC METAL POLYAMIDE CONJUGATES$32,416
F32 · FY2000 · GM